NBY: Bagan rega target NovaBay Pharmaceuticals

Historical price action for NovaBay Pharmaceuticals (NBY) on the GURU.Markets platform is currently at 4.25. NovaBay Pharmaceuticals is seeking to expand its product range through skin regeneration agents to reduce reliance on a single popular product. Despite patent protection and regulatory approval, the business faces intense pressure from industry behemoths. High customer loyalty to the Avenova brand ensures a stable cash generator.

This indicator aggregates average target share prices from leading investment banks, enabling real-time tracking of market expectation dynamics between reporting periods. Analyzing this composite benchmark for NovaBay Pharmaceuticals (NBY) share value, combined with ESG modernization and biodegradable packaging costs, helps assess the asset's resilience to biopharmaceutical regulatory risks.